600535.SH
天士力
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 14.82
−1.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 8.3B | 8.2B | 8.5B | 8.7B | 8.6B |
| Cost of Revenue | 2.7B | 2.7B | 2.8B | 2.9B | 3.1B |
| Gross Profit | 5.7B | 5.5B | 5.7B | 5.8B | 5.5B |
| Operating Expenses | |||||
| R&D Expense | 674.2M | 685.7M | 830.1M | 917.3M | 845.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 333.5M | 334.2M | 345.4M | 342.4M | 374.0M |
| Selling & Marketing Expense | 3.0B | 3.0B | 3.0B | 3.0B | 2.9B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 4.2B | 4.1B | 4.3B | 4.4B | 4.3B |
| Cost and Expenses | 6.8B | 6.8B | 7.1B | 7.2B | 7.4B |
| Operating Income (EBIT) | 1.4B | 1.4B | 1.1B | 1.2B | (160.1M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 1.4B | 1.3B | 1.1B | 1.2B | (167.6M) |
| Income Tax Expense | 305.0M | 283.9M | 209.6M | 204.5M | 180.8M |
| Bottom Line | |||||
| Net Income | 1.2B | 1.1B | 955.6M | 1.1B | (264.2M) |
| Earnings from Cont. Ops | 1.1B | 1.1B | 859.1M | 1.0B | (348.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 1.2B | 1.1B | 955.6M | 1.1B | (264.2M) |
| Per Share | |||||
| Basic EPS | CN¥0.78 | CN¥0.74 | CN¥0.64 | CN¥0.72 | (CN¥0.18) |
| Diluted EPS | CN¥0.78 | CN¥0.74 | CN¥0.64 | CN¥0.72 | (CN¥0.18) |
| Revenue Per Share | CN¥5.59 | CN¥5.52 | CN¥5.69 | CN¥5.83 | CN¥5.88 |
| Shares | |||||
| Basic Shares Outstanding | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B |
| Diluted Shares Outstanding | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B |
| Profitability Metrics | |||||
| EBITDA | — | 1.8B | 1.6B | 1.7B | 288.6M |
| D&A | — | 464.6M | 502.5M | 516.1M | 448.7M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026